Chlorthalidone
As of the edition of 20 October 2026, Chlorthalidone is a small molecule: marketed, first approved in 1964 (ES); acts on SLC12A3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Combipres
- First approved
- 1 December 1964 (ES)
- Approvals on record
- 25 in 5 regions
- Holder of the most recent approval
- PRM Pharma; 12 holders in all
- Registered trials
- 57, 9 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Hormones; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Chlorthalidone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A3 | Solute carrier family 12 member 3 | P55017 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 4 | 1 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 8 | 5 | 1 | 1 |
| Phase 3 | 25 | 20 | 0 | 4 |
| Phase 4 | 14 | 5 | 2 | 3 |
| All trials | 57 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Applicant and Lead sponsor of trials | 2007 to now |
| Bausch Health | Acquired holder | 2012 to now |
| Casper Pharma | Acquired holder | 2016 to now |
| PRM Pharma | Later holder | 2025 to now |
| Sanofi | Applicant |